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Development of an Efficient Dual-Action GST-Inhibiting
Anticancer Platinum(IV) Prodrug
Keefe Guang Zhi Lee,[a] Maria V. Babak,[a] Andrea Weiss,[b] Paul J. Dyson,[c]
Patrycja Nowak-Sliwinska,*[b] Diego Montagner,*[d] and Wee Han Ang*[a]
Introduction
Cisplatin (cDDP) constitutes one of the most common chemo-
therapy options for treating a wide variety of cancers today.[1]
However, their continued development is hampered, at least in
part, by platinum-associated drug resistance. For example,
some types of cancer, colorectal cancer, possess intrinsic resist-
ance to cDDP while others, for example, ovarian cancer, devel-
op acquired resistance after successive rounds of chemothera-
py.[2] The proliferation of these adapted tumors leads to subse-
quent generations of cancer cells being increasingly able to
cope with the same dose of cDDP through decreased uptake,
increased efflux, or through improved DNA repair mecha-
nisms.[3] Over time, the effectiveness of the platinum-based
chemotherapy regimen diminishes, invalidating it as a viable
treatment option, and decreasing the patient’s chances of sur-
vival. It would be advantageous, therefore, to devise new drug
treatment options that are able to concomitantly overcome re-
sistance mechanisms and significantly enhance efficacy.
Combination therapy has become an increasingly useful
strategy for cancer treatment. The basic premise is that a com-
bination of appropriately chosen drugs, usually with comple-
mentary mechanisms, would have effects that are synergistic,
producing an overall result that is greater than the sum of the
individual drugs’ effects. For example, the combination of pa-
clitaxel and carboplatin is the standard-of-care against ovarian
cancer. Paclitaxel inhibits DNA repair in the cancer cells follow-
ing carboplatin-induced DNA damage, thereby promoting cell
death of the malignant ovarian cancer cells.[4] Drug synergy
may also be achieved when one drug boosts the effectiveness
of the other by increasing the residence time of the latter in
vivo, through blocking drug excretion by transport pumps or
rendering detoxification mechanisms inactive. For instance, fla-
vonoids were found to be able to affect the accumulation of
doxorubicin in HCT-15 colon cancer cells through binding with
P-glycoprotein, an efflux pump for cytotoxic drugs.[5] One nota-
ble detoxification enzyme implicated in platinum-based drug
resistance is glutathione S-transferase (GST), which catalyzes
the conjugation of glutathione (GSH) to xenobiotics such as
cisplatin, and facilitates their excretion via the mercapturic acid
pathway.[6] In fact, it has been shown that the role of GST is so
significant that its activation confers cisplatin resistance upon
breast cancer cells.[7]
The GST inhibitor ethacrynic acid (EA), is known to sensitize
cancer cells to platinum-based cell death mechanisms and,
more generally, to boost the sensitivity of resistant cancer cells
toward alkylating agents.[8] In addition, the strategy of tether-
ing other molecules, including anticancer drugs, to a PtIV scaf-
fold is widely used in the pursuit of increasingly effective
cancer therapies.[9] Based on these data, we designed the
cDDP–EA conjugate 1, a PtIV prodrug that should release cDDP
and two EA moieties in reducing intracellular conditions, with
The cytotoxicity of cisplatin (cDDP) is enhanced when co-ad-
ministered with ethacrynic acid (EA), a glutathione S-transfer-
ase (GST) inhibitor. A PtIV–EA conjugate containing a cDDP
core and two axial ethacrynate ligands (compound 1) was
shown to be an excellent inhibitor of GST, but did not readily
release a PtII species to exert a synergistic cytotoxic effect. In
this study, a redesigned PtIV construct composed of a cDDP
core with one axial ethacrynate ligand and one axial hydroxido
ligand (compound 2) was prepared and shown to overcome
the limitations of compound 1. The EA ligand in 2 is readily re-
leased in vitro together with a cytotoxic PtII species derived
from cisplatin, working together to inhibit cell proliferation in
cDDP-resistant human ovarian cancer cells. The in vitro activity
translates well in vivo with 2, showing effective (~80 %) inhibi-
tion of tumor growth in a human ovarian carcinoma A2780
tumor model, while showing considerably lower toxicity than
cisplatin, thus validating the new design strategy.
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the constituent parts acting in concert to enhance the activity
of cDDP (Figure 1).[10] To our knowledge, 1 was the first such
dual-action PtIV complex which combined a bioactive axial
ligand with a cytotoxic PtII-based core template. Since the pub-
lication of its synthesis and properties in 2005, a multitude of
other PtIV complexes with multiple modes of action have been
reported, including examples of complexes with enhanced cy-
totoxicity, immuno-chemotherapeutic properties, targeting ca-
pabilities, selective activation for photodynamic therapy, or
complexes linked with other reporters for theranostics.[11]
Despite our intention during its design, 1 functioned as a
highly potent, but suicidal GST inhibitor in vitro with the Pt
moiety being sandwiched at the GST dimer interface by bridg-
ing Cys101 residues.[12] It seems likely that cDDP could not be
efficiently released from 1 due to its low reduction rate. Fur-
thermore, 1 exhibited a strong affinity to GST because the two
EA moieties were able to directly interact with both of the sub-
strate binding pockets in the GST dimer. Hence, we sought to
overcome the limitations of 1 by decreasing the reduction po-
tentials of the PtIV construct, as well as by lowering the GST
binding affinity through structural design.[13] Herein, we report
a new PtIV prodrug scaffold, 2, containing a single axial EA
ligand, and evaluated its properties against 1, most notably its
GST inhibition potency, cytotoxicity, and reduction kinetics.
Due to the superior properties of 2, an in vivo study was also
performed that demonstrates the high clinical potential of this
new rationally designed PtIV drug.
Results and Discussion
Chemistry
The PtIV complex 1 was synthesized using a modified literature
procedure.[10] Oxalyl chloride was first used to transform EA
into the activated acid chloride, which was then coupled to ox-
oplatin. Both axial OH ligands reacted directly with EA acyl
chloride in an esterification reaction to form 1 in moderate
yield (Scheme 1). This methodology could not be applied to
synthesize the monofunctionalized variant 2, due to the high
electrophilicity and reactivity of EA acyl chloride even with sto-
ichiometric control of the reagents. To circumvent this prob-
lem, EA was instead activated by coupling the carboxyl group
to N-hydroxysuccinimide (NHS). Being a weaker electrophile
than EA acyl chloride, the NHS ester derivative reacted with ox-
oplatin at a slower rate, enabling the monosubstituted PtIV
complex 2, to be obtained as the major product when a slight
excess of oxoplatin was used. Preparative reverse-phase HPLC
(RP-HPLC) was used to further purify the products to >99 % to
ensure sufficient purity for biological testing.
Biological assays
Inhibition of GST activity
The GST inhibitory activity of 2 was determined along with 1,
cDDP, and free EA using the established 1-chloro-2,4-dinitro-
benzene (CDNB) photometric assay protocol adapted from
Habig et al. , using commercial GST enzymes purified from
Figure 1. Structures of cDDP, EA, the previously reported PtIV conjugate 1,
and new conjugate 2 described in this study.
Scheme 1. Synthesis of PtIV–EA complexes 1 and 2.
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human placenta as a realistic model of human GST in vivo.[14]
Consistent with the previous study, 1 was found to be the
most potent GST inhibitor, two orders of magnitude more
potent than 2 and EA. Removal of an EA moiety significantly
diminishes the GST inhibitory activity of 2 relative to 1 based
on IC50 and calculated Ki data (Table 1). In an earlier solid-state
structural analysis of GSTP1-1 single crystals soaked with 1, we
observed that 1 was ideally oriented to directly interact with
each of the EA-binding sites on the dimeric GST enzyme (one
binding site per GST monomer). Furthermore, the Cys101 resi-
dues at the dimer interface could opportunistically reduce and
bind Pt covalently, giving rise to the strong multimodal interac-
tion between GSTP1-1 and 1.[12] The removal of one EA moiety
would prevent these synergistic interactions, enabling 2 to
function as a conventional inhibitor in a similar manner to EA,
validating our design strategy. Based on the Lineweaver–Burk
plots, the modes of inhibition for all compounds tested were
found to be noncompetitive with respect to CDNB (see Sup-
porting Information (SI)).[15] This differs from earlier reports due
to different GST enzymes used as well as incubation times.[12, 16]
Upon prolonged exposure to GSH, EA can form an EA–GSH co-
valent adduct conjugate that exhibits different modes of GST
inhibition, noncompetitive with respect to CDNB, as compared
with unconjugated EA.[17]
Reduction rates of PtIV prodrug complexes
To examine the possibility of 1 and 2 being viable prodrugs
which could be easily reduced in vivo, a reduction kinetics
study was carried using ascorbate as the biological reductant.
We earlier showed that under reducing conditions, PtIV com-
plexes with both axial ligand positions occupied by carboxyl-
ate ligands were significantly more resistant to reduction than
congeners with a carboxylate and a hydroxide at the axial
ligand positions.[13] These mono-carboxylate PtIV complexes
were prone to reduction because the hydroxido ligand facili-
tated H-bonding to the ascorbate reductant, thus accelerating
the reduction rates. While this study was intended to mimic
biological conditions, the poor solubility of 1 in aqueous
media necessitated the preparation of a DMSO stock solution,
and addition of THF co-solvent to prevent 1 from precipitating
out of the reaction mixture. By comparison, 2 was more solu-
ble in phosphate buffer at the required concentrations due to
the substitution of the hydrophobic ethacrynate ligand with
the hydrophilic hydroxide moiety. Initially, a biologically rele-
vant ascorbate concentration of 3 mm was used, and the con-
centration of 1 was lowered to the point where ascorbate was
in an approximate 300-fold excess. This was done to achieve
pseudo-first-order kinetics, where any changes in the reaction
rate could be assumed to be due only to changes in the PtIV
complex concentration. Aqueous stabilities of 1 and 2 were as-
certained over a period of three days, to ensure that the disap-
pearance of the starting material would be only due to the re-
duction reaction, and not due to unwanted side-reactions. In
the absence of reductants, 1 and 2 were found to be stable in
aqueous solutions.
Reduction rates were determined using HPLC to quantify re-
sidual levels of 1 and 2 after addition of ascorbate (Table 2).
While the reduction of 1 under the aforementioned conditions
(3 mm Asc) could be readily assessed by monitoring the de-
crease of peak area, the peak representative of 2 could not be
observed even at the point of the first HPLC injection, despite
a more concentrated stock solution being used. We concluded
that 2 was much more rapidly reduced under the same condi-
tions used for 1, validating our initial hypothesis. Indeed, the
ascorbate concentration had to be lowered by a factor of 200
before kinetics data were able to be obtained for the reduction
of 2. The dramatic difference in the reduction rates, via a
simple ethacrynate ligand substitution, showed that 2 was
much more susceptible to reduction than 1, and has the po-
tential to be intracellularly reduced before interacting with its
biological targets.
Table 1. Enzyme assays of GST inhibitors.
Compound Calcd Ki [nm] IC50 [nm]
[a] KM [mm]
1 47:6.6 38.7:4.2 0.69:0.02
2 899:117 2800:600 0.68:0.04
EA 2260:460 7920:1070 0.76:0.04
cDDP N.D.[b] 19 900:2900 N.D.
[a] Values are the mean:SD from at least three independent experi-
ments. [b] Ki was not calculated for cisplatin, as its mode of inhibition
was not determined.
Table 2. Reduction kinetics of PtIV complexes.
Compound [Asc] [mm] t1=2 [min] k [V 10
@3 min@1]
1 3.0 291 2.38
2 0.015[a] 8.55 81.1
[a] Complete reduction occurred instantaneously at 3.0 mm [Asc] .
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In vitro studies
The ability of 2 to inhibit cancer cell proliferation was evaluat-
ed against the A2780 ovarian cancer cell line and its cDDP-re-
sistant variant, A2780/cisR, using the MTT assay with 1, cDDP,
and EA as controls (Table 3). Remarkably, 2 was the most
potent compound against A2780 and A2780/cisR with IC50
values in the same order of magnitude as 1. Both 1 and 2 ex-
erted good cytotoxicities against the tested cell lines with IC50
values lower than cDDP. Notably, even if apparently they were
not able to overcome cDDP resistance in A2780/cisR (resist-
ance factors of 3.7, 7.1 and 7.0 for 1, 2 and cisplatin, respec-
tively), the activity of 2 is still eight times higher than that of
cisplatin (IC50 0.50 mm for 2 versus 4.11 mm for cisplatin). They
were also more cytotoxic than organometallic complexes
based on RuII and OsII centers modified with EA.[18] This en-
hancement in cytotoxicity could arise from separate factors.
The ethacrynate ligand increases the lipophilicity of the com-
plexes, which would increase cellular uptake and accumulation
relative to cDDP. Based on the data collected, it is unlikely that
increased cellular accumulation is the dominant factor, as 1 is
more lipophilic than 2 and therefore should be significantly
more cytotoxic than 2, whereas the opposite was observed ex-
perimentally.
The ethacrynate moiety potentiates the antiproliferative ac-
tivity of the PtIV complexes by inhibiting GST detoxification
pathways as designed. To confirm this hypothesis, cellular GST
activities were determined after exposure to 1 and 2. Briefly,
A2780 cells were exposed separately to 1, 2, EA or cDDP for
90 min. Thereafter, the cells were harvested, lysed via freeze
and thaw, and their intracellular GST activities determined
using the afore-mentioned CDNB-GSH assay (Table 4). The data
were normalized to EA equivalents—EA itself and 2 both con-
tained one EA equivalent per molecule, while 1 contained two
EA equivalents. Therefore, half the amount of 1 was used com-
pared with 2 and EA. Based on the obtained results, residual
GST levels after treatment with 1 and 2 were shown to be
dose-dependent, and independent of antiproliferative activity.
Intracellular GST activities in cells treated by 2 at 60 mm were
significantly inhibited, indicating that 2 could directly interfere
with its intended biological target. Notably, despite using half
the dose, 1 inhibited intracellular GST activity more effectively
than 2 or EA, reaffirming earlier reports that it behaves as an
efficient GST inhibitor. In comparison, EA was expected to be
poorly active due to its carboxylic acid moiety, which would
hinder its ability to traverse the cellular membrane. The GST in-
hibition property of cisplatin is similar to 2 at lower dose but is
much lower at higher concentration and does not seem to be
dose dependent. The lower dose used in this essay (10 mm) is
ten times higher than the IC50 concentration in A2780 cells but
the values refer to 90 mins incubation time with respect to
72 hours for the MTT test. Taken together, the data suggest 2
could function as a PtIV prodrug capable of inhibiting GST at a
cellular level.
In vivo study
Based on the promising properties of 2 presented above, in
vivo studies were conducted to benchmark the activity of 2
relative to cDDP. The chorioallantoic membrane of the chicken
embryo implanted with A2780 ovarian tumors was used (see
SI).[19] The embryos were inoculated with tumor cells and treat-
ment with various doses of 2 or cDDP was initiated after the
appearance of vascularized tumors. Treatment was adminis-
tered intravenously on two consecutive days, once daily.
Tumor size and toxicity was monitored daily over a period of
eight days. Compound 2 inhibited tumor growth in a dose-de-
pendent manner. On the last day of the experiment, tumors in
the control group reached an average volume of 309 mm3
(represented as 100 % value of tumor volume in Figure 2 a).
The growth of tumors treated with 2 at a dose of 10 mg/
embryo/day (corresponding to 16 nmol) was significantly in-
hibited by 77 % (two-way ANOVA with post-hoc Dunnett’s mul-
tiple comparisons test versus the DMSO-treated control, ** in-
dicates p-value <0.01). This study showed that 2 is able to ef-
fectively inhibit tumor growth in vivo with the ability to retard
tumor growth is similar extension to that of cDDP at an equiv-
alent dose (Figure 2 b); however, cDDP is much more toxic, as
it resulted in more extensive embryo death at equivalent dose
levels (Figure 2 b–c). Therefore, it is possible that 2 might be as
potent as cDDP, while having an improved safety profile.
Conclusions
A monofunctionalized PtIV complex, 2, comprising a GST inhibi-
tor conjugated to a Pt-based core, was prepared with the goal
of accessing a PtIV prodrug motif that could dissociate readily
in an intracellular environment to yield a cytotoxic PtII deriva-
tive and a GST inhibitor. The novel complex was found to be
an effective GST inhibitor operating via a noncompetitive
Table 3. Inhibition of cell viability.
Compound IC50 [mm]
[a] Resistance
factor
A2780 A2780/cisR
1 0.14:0.03 0.52:0.12 3.7
2 0.07:0.02 0.50:0.13 7.1
EA 30.00:5 42.00:15 1.4
cDDP 0.59:0.08 4.11:0.68 7.0
[a] Values are the mean:SD from at least three independent experi-
ments.
Table 4. Residual intracellular GST activity (A2780 cells).
Compound [Low] [mm] Res. act. [%][a] [High] [mm] Res. act. [%][a]
1 5 54.9:17.6 30 18.3:2.2
2 10 81.3:7.3 60 45.3:2.6
EA 10 90.7:14.7 60 80.5:18.2
cDDP 10 84.2:14.2 60 72.2:14.4
[a] Values are the mean:SD from at least three independent experi-
ments.
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mechanism. The increased susceptibility of 2 to reduction rela-
tive to 1 was introduced by design using an asymmetric PtIV
scaffold containing a hydroxido axial ligand to enhance H-
bonding interactions with potential biological reductants. De-
spite containing one EA moiety compared with two in com-
pound 1, compound 2 remained a potent antiproliferative
agent against cDDP-sensitive and cDDP-resistant cancer cells.
Importantly, 2 was able to decrease tumor growth in vivo in a
chicken embryo with significantly decreased toxicities relative
to cisplatin, as evidenced by increased embryo survivals. Con-
sequently, monofunctional PtIV complexes that are more easily
activated by reduction in vitro and in vivo could become an
important class of rapidly activating PtIV prodrugs with dual
modes of actions.
Experimental Section
Materials : All reagents were purchased from commercial sources
and used without further purification. Solvents were used as re-
ceived, except for THF, which was dried using an MBraun SPS-800
solvent purification system. Ethacrynic acid (EA) was purchased
from Abcam Singapore and GST (from human placenta, 25–
125 units mg@1 protein) was purchased from Sigma–Aldrich. Cispla-
tin (cDDP), oxoplatin [cis-,cis-,trans-diamminedichlorodihidroxo
platinum(IV)] , and 1 were synthesized according to literature meth-
ods.[10, 20]
General instrumentation : 1H NMR spectra were recorded on a
Bruker Avance 500 MHz spectrometer. Chemical shifts are reported
in parts per million relative to residual solvent peaks. Electrospray
ionization mass spectra (ESI-MS) were obtained using a Thermo
Finnigan MAT ESI-MS system in negative ion mode. High-resolution
mass spectrometry was performed using a Bruker micrOTOFQ II
spectrometer in the negative ion mode. Elemental analyses
(carbon, hydrogen and nitrogen) were performed with a Perki-
nElmer 2400 series II analyzer. UV/Vis readings for the enzyme
assays were obtained on a BioTek Synergy H1 hybrid microplate
reader. Pt levels were determined on a PerkinElmer Optima ICP-
OES spectrometer by CMMAC, NUS. The purity of PtIV compounds
were determined using analytical HPLC on a Shimadzu Prominence
HPLC system, with a Shimpack VP-ODS C18 (5 mm, 120 a, 150 mm V
4.60 mm i.d.) column at room temperature at a flow rate of
1.0 mL min@1 with UV detection at 254 nm and 280 nm. Reduction
studies were carried out on the same system with modified condi-
tions (described below).
Synthesis of 1: The following procedure was adapted from a litera-
ture method.[10] EA (501 mg, 1.65 mmol) was dissolved in an excess
of oxalyl chloride (~2.5 mL), and the mixture was heated at reflux
under nitrogen at 70 8C for 1 h, by which time EA had completely
dissolved and all effervescence had ceased. The excess oxalyl chlo-
ride was removed by vacuum distillation at room temperature, and
the mixture was washed with THF (2 V 5 mL). The product, a light-
yellow liquid, was dried under vacuum. The product was dissolved
in acetone (10 mL) and oxoplatin (102 mg, 0.31 mmol, 0.2 equiv)
was added. The resulting mixture was heated at reflux with stirring
at 70 8C until the solid oxoplatin had completely dissolved and a
clear yellow solution was obtained (~15–30 min). Water (50 mL)
was added immediately to quench the reaction and the reaction
mixture was kept at 4 8C for 12 h, during which a white solid was
formed. The liquid phase was decanted, and the residual white
solid was washed with diethyl ether (2 V 10 mL). The product was
purified twice by dissolution in THF (5 mL) and precipitation using
hexane (~30 mL), then dried in vacuo (154 mg, 55 %, see SI for
characterization data).
Synthesis of EA–NHS : EA (607 mg, 2 mmol) and NHS (253 mg,
2.2 mmol, 1.1 equiv) were dissolved in dry THF (10 mL). N,N’-Dicy-
clohexylcarbodiimide (454 mg, 2.2 mmol, 1.1 equiv) was separately
dissolved in dry THF (5 mL) and added dropwise to the EA/NHS so-
lution. The mixture was stirred at room temperature for 6 h, during
which a white precipitate of dicyclohexylurea (DCU) formed. The
white precipitate was removed by filtration and the filtrate was
dried under vacuum to afford a white solid that was re-dissolved
in CH2Cl2 (50 mL). The solution was kept at 4 8C for 12 h and then
filtered again to remove any additional DCU that had precipitated
out. The filtrate was washed with saturated NaHCO3 solution
(40 mL), followed by water (40 mL), and dried with Na2SO4. The
white solid obtained after evaporation of the filtrate was dried in
vacuo (681 mg, 85 %).
Synthesis of 2 : EA–NHS (72 mg, 0.18 mmol) and oxoplatin (65 mg,
0.2 mmol, 1.1 equiv) were added to DMSO (5 mL) and the mixture
was stirred at 50 8C for 12 h. The undissolved oxoplatin was re-
moved by filtration and the filtrate was lyophilized. The residue
was dissolved in DMF (1 mL) and precipitated by addition of dieth-
yl ether (30 mL). The solid was isolated by centrifugation and
washed with cold acetone (5 mL), cold THF (5 mL), and diethyl
Figure 2. In vivo activity of 2 and cDDP in human ovarian carcinoma (A2780)
in the CAM model. a) Tumor growth curves represent the following condi-
tions: control (0.1 % DMSO), 2 (0.12–10 mg/embryo/day) and cDDP (10 mg/
embryo/day) as a positive control. b) Ex ovo embryo weight at the last (8th)
experimental day upon tumor resection. (c) Dose-dependent embryo death
rate on day 8. Significance is indicated versus the DMSO-treated control ;
*p<0.05, **p<0.01 (two-way ANOVA with post-hoc Dunnett’s multiple com-
parisons test). Error bars represent standard error of the mean.
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ether (2 V 10 mL) before the product was dried in vacuo (66.9 mg,
60 %, see SI for characterization data).
Purification of the PtIV complexes (1 and 2) by preparative
HPLC : Complexes 1 and 2 were obtained with a purity >99 %
using preparatory RP-HPLC from solutions of the respective com-
plexes in DMSO. The conditions used are as follows: YMC Pack-Pro
C18 semi-preparative column (250 mm V 10 mm i.d.), water-acetoni-
trile solvent system (total flow = 2 mL min@1) with gradient elution
(20 % to 80 % acetonitrile in 20 min, then maintained at 90 % aceto-
nitrile for 10 min, and immediately lowered back to 20 % acetoni-
trile, and run for a further 15 min), UV-vis detection at 254 and
280 nm. The fraction containing the desired compound was col-
lected for each run. The individual fractions were combined, and
the solvents were removed by lyophilization to afford the pure PtIV
complexes.
GST optimization : GST (1 mg) was dissolved in ultrapure water
(1 mL) to give a stock solution with a working concentration of
1 mg mL@1. GST solutions of different working concentrations were
made from this stock solution by varying the volumes of water
and stock solution used. Aliquots of each GST sample solution
(20 mL) were placed in triplicate wells of a clear 96-well plate, along
with a column of wells consisting of only ultrapure water (20 mL)
for the background reading. The master mix was made using ultra-
pure water (5400 mL), phosphate buffer (900 mL, 1 m, pH 6.5), and
freshly prepared solutions of GSH (900 mL, 100 mm in ultrapure
water) and CDNB (900 mL, 100 mm in EtOH). Using a multichannel
pipette, the master mix (180 mL) was introduced into each of the
previously loaded wells. After the addition was completed, UV ab-
sorbances (340 nm) were monitored using the kinetics setting on
the Gen5 program (18 s scan interval, 6 min total time). The gradi-
ent of the linear region (initial 180 s, corrected for background ab-
sorption) was obtained, and the average value of the three repli-
cates for each concentration of GST was taken to be the initial rate
of the reaction.
GST inhibition assay : Stock solutions of 1 (6.15 mm), 2 (18.61 mm),
and EA (10 mm) were prepared by dissolving the respective com-
pounds in DMSO. The cDDP stock solution (3.08 mm) was made by
dissolving solid cDDP in aqueous NaCl solution (100 mm). The con-
centrations of Pt-containing solutions were independently verified
using ICP-OES. Sample solutions of varying concentrations were
made for each compound by serial dilution of the stock solution
using ultrapure water (four-fold dilution, 6 cycles of serial dilution).
For each compound, aliquots of solution at each different concen-
tration (65 mL) were added to separate aliquots of GST stock solu-
tion (5 mL), and the mixtures were incubated at room temperature
with gentle shaking for 30 min. Ultrapure water was used as the
control. The master mix was prepared as previously described.
After incubation, aliquots of each sample solution of a particular
compound (20 mL) were loaded into triplicate wells of a clear 96-
well plate (seven inhibitor concentrations and one control V 3 repli-
cates and one blank with no enzyme). Using a multichannel pip-
ette, the master mix (180 mL) was introduced into each of the
wells, and the UV absorbances (340 nm) of those wells were imme-
diately tracked using the kinetics setting on the Gen5 program
(18 s scan interval, 6 min total time). The average gradient of the
linear region of the UV absorbance graph (initial 180 s, corrected
for background absorption) was obtained for each concentration
of inhibitor, and taken to be the initial rate of the reaction at that
specific inhibitor concentration; 50 % inhibitory concentrations
(IC50) were calculated from concentration-effect curves by interpo-
lation. Evaluation was based on means from at least three inde-
pendent experiments, each comprising three replicates per con-
centration level.
Enzyme kinetics assay : For each compound assessed, GST stock
solution (40 mL) and the required volume of the corresponding
stock solution were added to ultrapure water (600 mL final
volume). The solutions were incubated at room temperature with
gentle shaking for 30 min. Two sets of master mix were prepared;
one with CDNB added, and one without CDNB (the same volume
of EtOH was used instead). These two master mixes were mixed in
different proportions to obtain solutions of varying CDNB concen-
trations (see SI). After incubation, aliquots of the GST-inhibitor solu-
tion (20 mL) were loaded onto a 96-well microplate (eight CDNB
concentrations V 3 replicates and one blank). Aliquots of each
CDNB mix (200 mL V 4) were also separately loaded into wells of a
second microplate for expedient and simultaneous transfer. Using
a multichannel pipette, the various mixes (180 mL) were introduced
into a corresponding well of GST solution, and the UV absorbances
(340 nm) of those wells were immediately tracked using the kinet-
ics setting on the Gen5 program (18 s scan interval, 6 min total
time). The average gradient of the linear region (initial 180 s, cor-
rected for background absorption) was obtained for each CDNB
concentration, and taken to be the initial rate of the reaction at
that specific concentration of CDNB. The Lineweaver–Burk plot of
1/V against 1/[CDNB] was then plotted for the various inhibitors at
different concentrations.
Reduction study of 1: A stock solution of 1 (0.154 mm) in DMSO
was made and its concentration was determined accurately by ICP-
OES. Separately, a solution of sodium l-ascorbate (30 mm) in phos-
phate buffer (200 mm, pH 7.4) was made. The stock solution of 1
(120 mL), THF (200 mL), and phosphate buffer (1480 mL, 200 mm,
pH 7.4) were mixed in a HPLC vial and the reduction was initiated
by adding the sodium l-ascorbate solution (200 mL) into the vial,
capping it, and shaking vigorously for 5 s. The vial was then placed
in the HPLC autosampler, and the batch run was initiated. Injec-
tions (50 mL) were performed at 20-min intervals, and detection
was by UV (214 and 254 nm). The area of the starting material
peak was monitored over time. A Shimpack VP-ODS C18 analytical
column (5 mm, 120 a, 150 mm V 4.60 mm i.d.) was used, with an iso-
cratic elution method (total flow rate: 1 mL min@1, solvent system:
60 % acetonitrile and 40 % water).
Reduction study of 2 : A stock solution of 2 (0.205 mm) in phos-
phate buffer (200 mm, pH 7.4) was made and its concentration was
determined accurately by ICP-OES. Separately, a solution of sodium
l-ascorbate (0.3 mm) in phosphate buffer (200 mm, pH 7.4) was
made. The stock solution of 2 (100 mL) and phosphate buffer
(1800 mL, 200 mm, pH 7.4) were mixed in a HPLC vial. The reduc-
tion was started by adding the sodium l-ascorbate solution
(100 mL) into the vial, capping it, and shaking vigorously for 5 s.
The vial was then placed in the HPLC autosampler, and the batch
run was initiated. Injections (50 mL) were performed at 10 min in-
tervals, and detection was by UV (214 and 254 nm). The area of
the starting material peak was monitored over time. A Shimpack
VP-ODS C18 analytical column (5 mm, 120 a, 150 mm V 4.60 mm i.d.)
was used, with an isocratic elution method (total flow =
1 mL min@1, solvent system = 40 % acetonitrile and 60 % water).
MTT assay : The cytotoxicity of the compounds was determined by
a colorimetric microculture 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay. The cells were harvested from
culture flasks by trypsinization and seeded into Cellstar 96-well mi-
croculture plates (seeding density: 6000 cells per well). After the
cells had resumed exponential growth for 24 h, they were exposed
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to the compounds under investigation at different concentrations
in media for 72 h. The compounds (1, 2, cDDP, and EA) were dilut-
ed separately in complete medium to the desired concentrations,
and this solution (100 mL) was added to each well and serially dilut-
ed to other wells. After exposure for 72 h, compound solutions
were replaced with MTT in media (100 mL, 5 mg mL@1) and incubat-
ed for an additional 45 min. Subsequently, the medium was aspi-
rated and the purple formazan crystals formed in viable cells were
dissolved in DMSO (100 mL per well). Optical densities (570 nm)
were measured with a microplate reader. The quantity of viable
cells was expressed in terms of treated/control (T/C) values by
comparison with untreated control cells, and 50 % inhibitory con-
centrations (IC50) were calculated from concentration-effect curves
by interpolation. Evaluation was based on means from at least
three independent experiments, each comprising six replicates per
concentration level.
Determination of residual GST levels in treated A2780 cells : The
protocol was adapted from a literature protocol. Human ovarian
carcinoma A2780 cells were seeded into 6-well plates (seeding
density: 106 cells per well, 2 mL). After the cells were allowed to
resume exponential growth for 24 h, they were washed once with
sterile PBS, replaced with fresh growth medium and exposed to
the compounds (1, 2, EA, and cDDP) separately at the required
concentrations for 1.5 h, then washed with sterile PBS (2 V 1 mL).
After adding PBS (300 mL) to each well, cells were harvested using
cell scrapers, transferred into separate 1.5 mL microtubes and cen-
trifuged (250 V g) for 7 min. After removing the supernatant, the
cell pellets were re-dissolved in Protease Inhibitor Cocktail (70 mL,
in sterile PBS). The cells were disrupted by five cycles of freezing
and thawing, and centrifuged (13 000 rpm) for 15 min to separate
the cell pellet. The supernatant (20 mL) was added to triplicate
wells of a 96-well microplate. The master mix was made as per the
GST inhibition assay, and the GST inhibition assay was carried out
as previously described.
The chorioallantoic membrane model (CAM): A2780 human ovar-
ian carcinoma cells (ECACC, Salisbury, UK) were maintained in
RPMI-1640 cell culture medium supplemented with GlutaMAXQ
(Gibco, Carlsbad, CA, USA), 10 % bovine calf serum (Sigma–Aldrich,
St. Louis, MO, USA) and 1 % antibiotics (pen/strep, Sigma–Aldrich).
Fertilized chicken eggs were incubated in a hatching incubator (rel-
ative humidity 65 %, 37 8C) for seven days, as previously described.
On egg development day 7, 106 A2780 cells were transplanted on
the surface of the chorioallantoic membrane (CAM) as a 25 mL
hanging drop. Vascularized tumors appeared approximately three
days after inoculation on the surface of the CAM. Compound 2 or
cDDP were administered intravenously on treatment days 1 and 2,
after which tumor size and toxicity was monitored daily over a
period of eight days. Tumors were measured daily: volume = (larg-
est diameter)2 V (perpendicular diameter) V 0.5.
Statistical analysis : Statistical analysis was performed based on a
two-way ANOVA with post-hoc Dunnett’s multiple comparisons
test performed in GraphPad Prism.
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